FLT3LG and cancer: CDX-301 (developed by Celldex Therapeutics) is a soluble recombinant human protein form of the Fms-related tyrosine kinase 3 ligand (Flt3L) and has passed the phase 1 clinical trial for hematopoietic stem cell transplantation20 and cancer immunotherapy.21